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summary, all 6 deaths were among the pa-
tients with del22q, either related or unre-
lated to their immunodeficiency. This asso-
ciation was statistically significant [6/15 vs
0/22, difference –0.4, 95% CI –0.65 to
–0.15, P  .002].
In our experience microdeletion of
chromosome 22q11.2 appears associated
with poor overall outcome after surgical
treatment of PA-VSD with MAPCAs. We
believe that such a peculiarity, not neces-
sarily related to special anatomic cardiac
features associated with the syndrome it-
self, should justify the use of a protocol for
preoperative assessment of immunologic
status of patients with del22q undergoing
surgery for PA-VSD with MAPCAs and
the administration of a perioperative anti-
fungal prophylaxis when necessitated by a
depressed immunologic condition.
Within the population of patients with
complex congenital heart lesions, the prev-
alence of genetic syndromes is relevant.9
Genetic syndromes may influence both
clinical outcome and surgical results of
treatment of congenital heart defects, both
because of peculiar anatomic cardiac fea-
tures and because of associated extracar-
diac abnormalities.9,10 This is the main rea-
son that the possible association with a
genetic syndrome should always be in-
cluded among hypothetic risk factors
within the analysis of postoperative out-
come of congenital heart defects.
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Caveat against the use of FEIBA in
combination with recombinant factor
VIIa
To the Editor:
We appreciate the recent report from Bui
and colleagues1 on a fatal thrombosis after
administration of activated prothrombin
complex concentrate (FEIBA) in a patient
previously treated with recombinant acti-
vated factor VII (rFVIIa) for massive
bleeding during extracorporeal membrane
oxygenation. The activation of the coagu-
lation system by FEIBA is a rare but
known adverse reaction.2 A fatal thrombo-
sis after treatment with activated factor
VIIa and FEIBA has been described previ-
ously.3
Despite this, the hemostatic treatment in
this patients raises some further questions.
As the authors stated, the extracorporeal
circulation (ECC) induces a disseminated
intravascular coagulation–like state. A se-
rum level of fibrin degradation products of
4 supports this theory and moreover indi-
cates some degree of hyperfibrinolysis. Un-
fortunately, no information about the use of
antifibrinolytic agents (aprotinin, tranex-
amic acid) in this patient were provided.
We hypothesize that the use of antifibrino-
lytic agents might have attenuated the pro-
coagulant condition in this patient.
Fibrinogen is extensively consumed in
disseminated intravascular coagulation–
like states.4 Because fibrinogen levels were
not given for this patient, we have to spec-
ulate that fibrinogen levels in this patient
were below the normal range because of
profuse bleeding and elevated consump-
tion, resulting in high levels of fibrin deg-
radation products aggravating the bleeding
condition. On the other hand, we can spec-
ulate that the substitution of 22 units of
fresh-frozen plasma and, in particular, 30
units of cryoprecipitates may also have re-
stored supernormal fibrinogen and factor
VIII:c levels, which in this patient may
have promoted a procoagulant potential
possibly associated with the risk of throm-
bosis after administration of FEIBA.
Under conditions of profuse bleeding in
association with a disseminated intravascu-
lar coagulation–like state, antithrombin ac-
tivity is important. Antithrombin activity is
decreased in ECC because of an elevated
consumption,5 and thus the inhibitory po-
tential of the plasmatic coagulation system
may not have been preserved in this patient
despite the substitution of 22 units of fresh-
frozen plasma. Unfortunately, no informa-
tion regarding antithrombin activity was
provided. It is hypothesized that the substi-
tution of antithrombin might have reconsti-
tuted the inhibitory potential of the plas-
matic coagulation system, attenuating the
procoagulant response to FEIBA.
Finally, we agree with the authors that
the prothrombotic potential of rFVIIa is
low, because this reflects our own observa-
tions.6 From in vitro results,7 we have to
assume that the prothrombotic potential of
FEIBA is higher. However, we disagree
with the authors’ conclusions on two
points. First, despite the high safety profile
of rFVIIa, the use of rFVIIa in cardiac and
transplantation surgery needs further inves-
tigation before its use can be recom-
mended, in particular for patients with pro-
thrombotic risk factors.8 Second, the
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1667
initiation of heparin anticoagulation before
treatment with factor concentrates in bleed-
ing patients under ECC is controversial,
because the effect of heparin is antithrom-
bin dependent. We recommend the close
monitoring and substitution of antithrom-
bin in conditions with an ongoing activa-
tion of the hemostatic system. Although
there is no evidence from the literature yet,
inhibitor levels (in particular antithrombin)
should be kept within the normal range
before administration of factor concen-
trates to attenuate the procoagulant re-
sponse, possibly resulting in thromboem-
bolic complications.
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Is there an evidence in favor of off-
pump coronary artery bypass?
To the Editor:
We read with interest the report of Mack
and colleagues1 that shows “improved out-
come in coronary artery bypass grafting
with beating-heart techniques.” In the era
of evidence-based medicine and megatri-
als, class A level evidence will remain the
standard tool that forces change of direc-
tion of currently applied surgical proce-
dures, including coronary artery bypass
grafting. We concede that in the absence of
major prospective randomized trials2,3 ret-
rospective studies such as this may contrib-
ute enough evidence to sway the balance in
favor of or against off-pump coronary ar-
tery bypass grafting (OPCAB).
However, we wish to highlight two is-
sues that could have a significant impact on
the conclusions derived from the study.
First, at one point the authors claimed that
the conversion rate was 2.9% and stated
that “these patients were analyzed with the
on-pump group.” Later, however, they re-
ported a conversion rate of 1.6% and sug-
gested that the analysis was performed on
an intent-to-treat basis (that conversions
were analyzed with the OPCAB group).
These conflicting statements require further
clarification. Second, the need for a sub-
group analysis of the cases converted from
OPCAB to an on-pump procedure cannot
be overemphasized. This analysis may pro-
vide the answer to a number of important
questions regarding OPCAB, such as indi-
cations, timing, predictors, and, more im-
portantly, the outcome of conversion in
terms of mortality and morbidity.
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Short esophagi and a long career
To the Editor:
Professor J. Leigh Collis, a prominent sur-
geon, made several contributions to the de-
velopment of the thoracic and cardiac sur-
gery. However, he was immortalized and
known worldwide for his work on gastro-
plasty, originally published in this Journal
46 years ago.1
I contacted by letter the then-90-year-
old Professor Collis, asking for data to be
used in an article concerning the history of
esophageal surgery. I was honored with a
concerned and pleasant reply. After our last
contact, however, I received the grievous
notice that Professor Collis had died on
February 4, 2003.
It is fitting to pay homage to this singu-
lar character in the history of the esopha-
geal surgery in the same Journal that im-
mortalized him.
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Problems with complication rate
analysis
To the Editor:
In a recent issue of this Journal, Grunk-
emeier and Wu1 analyzed complication
rates after bileaflet valve implantation by
means of pooled data and regression anal-
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